ReachMD’s Post

In an ongoing collaboration, our International Thyroid Oncology Group (ITOG) experts summarize latest updates on the molecular changes & clinical management of oncocytic #thyroidcancer just published in JAMA Otolaryngology https://ow.ly/NiJu50QWJke #medtwitter #endotwitter #oncocytic #hurthlecell #thyroid

Exciting results and updates from key studies presented at American Society of Clinical Oncology (ASCO) #GI24 🔑GALAXY ➡️ dynamic change in ctDNA of more than 50% at 6 months of adjuvant chemotherapy was associated with improved disease-free survival (51% vs. 29%) in CRC 💧COBRA ➡️ pre-planned analysis showed that use of chemotherapy did NOT increase the rate of ctDNA clearance compared to observation only in those patients with low risk stage II CRC with detectable ctDNA levels after surgery 🔑 CheckMate-8HW ➡️ a combination of nivolumab and ipilimumab led to a 79% reduction in the risk of disease progression or death compared to standard chemotherapy with LESS toxicity in patients with MSI-H/dMMR CRC 🔑 SKYSCRAPER-08 ➡️addition of tiragolumab to atezolizumab and chemotherapy improves PFS and OS without compromising safety in advanced esophageal squamous cell carcinoma 🔑 EMERALD-1 ➡️ a combination of durvalumab, bevacizumab and TACE improved PFS in unresectable HCC #gioncology #liquidbiopsy #ctDNA Rebecca Previs

Join us for this webinar on using ICG in Gynae-oncology #GYN #ICG #GYNE #Oncology

Continuing our examination of novel therapy alternatives to radical cystectomy…   The largest retrospective study of sequential intravesical gemcitabine/docetaxel for BCG-unresponsive non-muscle-invasive bladder cancer resulted in a 1-year recurrence-free survival rate of 60% and a 2-year rate of 46%, with high grade recurrence-free survival rates of 65% (1 year) and 52% (2 years) (Steinberg et al, Journal of Urology, 2020).   Smaller retrospective studies have evaluated salvage electromotive drug administration (EMDA) of mitomycin in the BCG-failure setting. For CIS patients, the high-grade recurrence-free survival rates were: 50% at 1 year, 44% at 18 month and 25% at 2 years (Di Gianfrancesco et al, Clinical Genitourinary Cancer, 2021).   #medicalinnovation #bladdercancer #HIVEC #CombatMedical 

Continuing our examination of novel therapy alternatives to radical cystectomy…   The largest retrospective study of sequential intravesical gemcitabine/docetaxel for BCG-unresponsive non-muscle-invasive bladder cancer resulted in a 1-year recurrence-free survival rate of 60% and a 2-year rate of 46%, with high grade recurrence-free survival rates of 65% (1 year) and 52% (2 years) (Steinberg et al, Journal of Urology, 2020).   Smaller retrospective studies have evaluated salvage electromotive drug administration (EMDA) of mitomycin in the BCG-failure setting. For CIS patients, the high-grade recurrence-free survival rates were: 50% at 1 year, 44% at 18 month and 25% at 2 years (Di Gianfrancesco et al, Clinical Genitourinary Cancer, 2021).   #medicalinnovation #bladdercancer #HIVEC #CombatMedical 

🌟 Join us on a journey through the stages of colon cancer treatment! 🌟 From early detection to advanced therapies, our latest video covers it all. Learn about the crucial role of surgery in early-stage tumors, the power of adjuvant therapy for higher-risk stages, and the cutting-edge treatments like chemotherapy, targeted therapy, and immunotherapy for metastatic cases. We'll also delve into exciting advancements like personalized medicine and genetic testing, offering tailored options for better outcomes. Let's navigate this journey together towards a healthier life! 💪 --- Video link: https://bit.ly/49Vzm2c . . . . #coloncancerawareness #earlydetectionsaveslives #cancertreatmentoptions #surgeryforcancer #adjuvanttherapy #chemotherapy #targetedtherapy #immunotherapy #metastaticcancer #personalizedmedicine #genetictesting #cancerresearch #cancerawareness #healthjourney #fightcancertogether #betteroutcomes #cancersurvivor #medicaladvancements #treatmentoptions #coloncancerfight #cancersupport #navigatingcancer #healthierlife #coloncancertreatment #joinourjourney

Pathological complete response PCR is very important for survival as well as organ preservation. OCR will never be reached without cooperation between sergeants, oncologists abd pathologists which means team based planning of treatment = MDT. ESMO - European Society for Medical Oncology OncoDaily

An economic evaluation demonstrates that use of tumor-informed ctDNA testing to guide adjuvant chemotherapy in post-surgery patients with stage II colon cancer results in cost savings for both commercial health and Medicare Advantage payors. https://ja.ma/4bHAQ1I

Considering switching to transperineal (TPBx) over transrectal (TRBx) prostate biopsies? Our blog breaks down the benefits and considerations for each biopsy method. Freehand TPBx prostate biopsies are gaining momentum worldwide due to various advantages over the TRBx approach, including: - Significantly reducing post-biopsy complications without quinolone antibiotics, especially urosepsis - Superior targeting of anterior regions - Can be performed in-office with local anesthesia For more information, check out our recent blog, "Transperineal & Transrectal Prostate Biopsies For Cancer Detection": https://hubs.ly/Q02n33Cq0

Perihilar cholangiocarcinoma poses unique challenges for surgeons and patients. Explore the latest insights on major hepatectomy by Soreide in the latest issue of Annals of Surgical Oncology: https://ow.ly/b7fm50ThJ9I #SurgicalOncology #FeaturedArticle